bispecific antibodies

Photo
26.07.2024 • News

Dren Bio, Novartis to Develop Bispecific Cancer Antibodies

US biopharmaceutical company Dren Bio, a developer of novel antibody therapeutics, has entered into a collaboration with Novartis Pharma, a subsidiary of Novartis. The collaboration will focus on the discovery and development of therapeutic bispecific antibodies for cancer using Dren Bio’s proprietary targeted myeloid engager and phagocytosis platform.

Photo
29.05.2024 • News

J&J Acquires Rights to Numab's Bispecific Antibody NM26

US healthcare giant Johnson & Johnson (J&J) agreed to acquire Yellow Jersey Therapeutics (YJT) from biotechnology company Numab Therapeutics in an all-cash transaction valued at approximately $1.25 billion, giving it worldwide rights to the novel, investigational bispecific antibody NM26.

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.